BiomX

Company Overview

Snapshot

Founded in May 2015 by Eran Elinav, Rotem Sorek, and Tim Lu, BiomX operates with 51–200 employees. The company has raised a total of $146.5M across 11 funding rounds from 15 investors. In April 2026, BiomX acquired Zorronet, an autonomous AI command-and-control platform, expanding its presence in security and defense markets.

Business overview

BiomX is a clinical-stage microbiome company focused on developing natural and engineered phage cocktails to treat chronic diseases such as cystic fibrosis, atopic dermatitis, inflammatory bowel disease, primary sclerosing cholangitis, and colorectal cancer. The company leverages computational and synthetic biology platforms, along with research from the Weizmann Institute of Science and MIT, to identify proprietary bacterial targets and customize phage compositions. BiomX also aims to expand into security and defense markets by commercializing technologies that address national security, emergency response, and critical infrastructure protection.

Strategic signal

In April 2026, BiomX acquired Zorronet, an autonomous AI command-and-control platform. This strategic acquisition signals BiomX's intent to diversify beyond its core microbiome therapies into the security and defense sectors, leveraging AI to identify and commercialize technologies for national security and critical infrastructure protection. This move indicates a significant strategic pivot and potential new revenue streams for investors.

Company Intelligence Q&A

What was a significant recent acquisition by BiomX?

In April 2026, BiomX acquired Zorronet, an autonomous AI command-and-control platform, to expand its presence in security and defense markets.

What was the outcome of the Phase 1b/2a trial for BX004 in cystic fibrosis patients?

In November 2023, BiomX announced positive topline results from Part 2 of the Phase 1b/2a trial evaluating BX004 for the treatment of chronic pulmonary infections in patients with cystic fibrosis.

When did BiomX merge with Adaptive Phage Therapeutics?

In March 2024, BiomX announced its entry into a merger agreement with Adaptive Phage Therapeutics, accompanied by a concurrent $50 million financing.

What was a key development regarding BX004 in October 2025?

In October 2025, BiomX provided a program update and announced new FDA feedback that could potentially expand the development pathways for BX004.

What was the most recent financial result announcement from BiomX?

In November 2025, BiomX reported its Third Quarter 2025 Financial Results and provided program updates.